AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04945577 — intervention group
Intervention type: OTHER
Intervention: 25 OH Vitamin D Level
Description: Laboratory measurement of patient's 25 OH vitamin D level in unit of ng/dl
Study NCT02716805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab was administered as an intravenous (IV) infusion over 60 ± 5 minutes at a fixed dose of 75 mg, regardless of weight.
Study NCT02716805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab was administered as an IV infusion over 60 ± 5 minutes at a fixed dose of 1500 mg for subjects weighing > 30 kg. If a subject's body weight dropped to ≤ 30 kg on study, the subject was dosed at 600 mg for as long as the body weight remained ≤ 30 kg.~When applicable, the durvalumab infusion was to start at least 60 minutes after the end of the tremelimumab infusion.
Study NCT02716805 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar-13
Description: Prevnar-13 was administered as an intramuscular injection. The Prevnar-13 dose and the tremelimumab dose were to be separated by a minimum of 48 hours.
Study NCT02716805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan was administered as an IV infusion according to institutional standard of care and local prescribing information.
Study NCT02059252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartMatrix dermal replacement scaffold
Description: SmartMatrix dermal replacement scaffold
Study NCT04605042 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wet suction
Description: Before pucturing the lesion, the stylet was removed and the needle was pre-flushed with 1-2 mL of saline using a 10-mL syringe, the endoscopist then punctured the lesion and replaced the 10-mL syringe with a 10-mL pre-vacuum syringe
Study NCT01727635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: body-mind-spirit group therapy
Description: 8-session therapy
Study NCT03123354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: O3 regional oximeter sensor
Description: Noninvasive sensor that is placed on the forehead for measurement of oxygenation in the area under the sensor
Study NCT01544777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study IOL
Description: Aspheric IOL for correction of aphakia
Study NCT01544777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hoya iSert 751
Description: Model 751 in one eye, standard IOL in other eye
Study NCT01544777 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Negatively aspheric IOL
Description: Negatively aspheric IOL in both eyes
Study NCT04288804 — intervention group
Intervention type: DEVICE
Intervention: Smartphone microphone sensor
Description: The volunteer will record themselves sustaining the short a vowel sound for 10 seconds.
Study NCT04288804 — intervention group
Intervention type: DEVICE
Intervention: Smartphone accelerometer sensor
Description: The volunteer's smartphone's accelerometer will record accelerometer data (positions on the x, y, and z axes) while the volunteer maintains 4 positions, each for 10 seconds.
Study NCT03375112 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block
Description: The patient will be brought to the block room within 30 minutes of arriving in recovery. An injection of local anesthetic into the fascia iliaca compartment using ultrasound guidance will be administered. The patient will then be transported back to recovery.
Study NCT03375112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patient will be brought to the block room within 30 minutes of arriving in recovery. An ultrasound probe will be placed to the skin and a blunt needle will be touched to the patient's skin in the area that a fascia iliaca compartment block would be performed. The patient will then be transported back to recovery.
Study NCT03375112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: A one time dose of 40 milliliters of 0.5% bupivacaine will be injected into the fascia iliaca compartment
Study NCT03171896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clown
Description: A medical clown will be offerred to the parturient and will spend time with her during labor as long as she will want it
Study NCT03171896 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: No clown will be present in the room during labor
Study NCT04605042 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard negative pressure suction
Description: after puncturing the lesion, the endoscopist removed the stylet and attached a 10-mL pre-vacuum syringe for aspiration.
Study NCT02713373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study NCT02713373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02713373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT04200573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ampreloxetine
Description: The study drug will be administered orally as a single Dose A tablet
Study NCT02683993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumenis Pulse 120H holmium laser system and 200 DFL ball tip fiber
Description: The Lumenis Pulse P120H will be utilized in high and low frequencies according to subjects group allocation.
Study NCT02496000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORMD-0801
Description: Oral Insulin
Study NCT02496000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo
Study NCT03543423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Description: Oral glucose tolerance test will be carried out with a glucose solution made up of 75g glucose dissolved in 300mL. To the glucose solution will be added 5g 3-OMG and 1g paracetamol 5g 3-OMG
Study NCT03543423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid mixed meal test
Description: A standardised liquid mixed meal test will be carried out using a standard liquid mixed meal (fresubin drink supplemented with 1g paracetamol).
Study NCT04241653 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Support Ventilation
Description: Ventilator will be adjusted to administer pressure at 10 cmH2O.
Study NCT04241653 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unparalyzed Pressure Control Ventilation
Description: Pressure controlled ventilation mode will be applied to obtain a volume of 8 ml/kg up to 20 cmH2O. The set respiratory rate will be 15 breaths/min then it is adjusted to achieve the end tidal CO2 levels between 35 and 40 mmHg as measured by capnography.
Study NCT03913130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR-110
Description: First treated eye: maintenance dose every 6 months, intravitreal administration Contralateral eye: loading dose followed by maintenance dose, every 6 months, intravitreal administration
Study NCT03826472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond Butter
Description: Natural almond butter
Study NCT00380146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulfadoxine-pyrimethamine
Study NCT02478281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Study NCT02731560 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab
Description: Rituximab was administered as an intravenous infusion as per approved protocol on Day 1 and day 14. The protocol stipulated the administration of intravenous hydrocortisone 100 mg and oral pheniramine maleate 43.5 mg as pre-medication. The Rituximab itself was given as a 1 gm infusion slowly over a period of 4-6 hours.~This was done either by a specialist nurse or a trained doctor.
Study NCT04241653 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paralyzed Pressure Control Ventilation
Description: Pressure controlled ventilation mode will be applied to obtain a volume of 8 ml/kg up to 20 cmH2O. The set respiratory rate will be 15 breaths/min then it is adjusted to achieve the end tidal CO2 levels between 35 and 40 mmHg as measured by capnography. Also, neuromuscular blockade will be achieved.
Study NCT04241653 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Mask Airway
Description: Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation; its size is chosen according to the body weight of the child.
Study NCT03249649 — intervention group
Intervention type: BEHAVIORAL
Intervention: Comprehensive Healthcare Needs Assessment
Description: Questionnaire focused on existing healthcare communication, treatment and services plus community needs in those three areas.
Study NCT00238888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: asthma control awareness
Description: Repeated assessments of the child's asthma control using the Asthma Quiz for Kidz, with recommendation for asthma education and medical visit
Study NCT00238888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Recommendation for asthma education and/or follow-up at the physician's discretion
Study NCT04495933 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg
Description: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg
Study NCT04495933 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg
Description: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg
Study NCT04495933 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg
Description: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg
Study NCT04495933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: sterile saline
Study NCT04241653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane in air/oxygen mixture of 40% will be titrated to achieve adequate depth of anesthesia to maintain immobilization of the eye.
Study NCT03427671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusin 500 Microspheres
Description: Occlusin 500 microspheres will be administered using a catheter directed to the uterine vasculature using fluoroscopy. The microsphere suspension will be administered to a near-stasis endpoint.
Study NCT02256371 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis sessions
Description: 1 session per week during 8 weeks
Study NCT01536730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Homework Intervention Strategy
Description: Participants assigned to intervention will receive a condom ditty bag containing 50 condoms (5 each of 10 types), a variety of 50 lubricants, an instructional DVD, and instructions for the intervention.
Study NCT02364518 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Snoreplasty
Description: The procedure will be performed under local anesthesia in the examination chair. The subject's throat will be anesthetized with benzocaine spray followed by infiltration of the soft palate with 4-5 milliliters of 1% lidocaine with 1:100,000 epinephrine. The TranQuill suture will be inserted into the soft palate tissues using a predescribed pattern.
Study NCT01081223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cancer vaccine plus immune adjuvant
Description: Tumor tissue is used for cancer vaccine. Following vaccinations, white blood cells are collected, stimulated and expanded, and are then reinfused. The infusion is followed by a course of low-dose IL-2.
Study NCT01916122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorestradiol (FES)
Study NCT01916122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT Imaging
Study NCT03605810 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This study is the development of algorithms/models to predict eGFR values and/or classes for patients at certain time point based on entries in claims database (demographic characteristics, clinical diagnoses, procedures and drug treatments) for a general population and a variety of use-cases (AF, CAD, T2DM patients sub-populations).
Study NCT02329522 — intervention group
Intervention type: DEVICE
Intervention: Ultrasonic Cardiac Output Monitor
Description: An Ultrasonic Cardiac Output Monitor (USCOM; USCOM Pty Ltd, NSW, Australia) is a non-invasive Doppler ultrasonography. It is capable of measuring haemodynamic parameters non-invasively and appears to be simple and rapid to use, portable, relatively inexpensive and has less potential complications compared with the standard technique, pulmonary artery thermodilution (PATD).~USCOM scans will be performed on patients to measure direct and derived haemodynamic variables, which will be performed in the supine position wherever possible. A transducer will be placed on the chest in either the suprasternal position to measure trans-aortic blood flow, or the left parasternal position to measure transpulmonary blood flow.
Study NCT02256371 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation group
Description: 1 relaxation session per week during 8 weeks
Study NCT03558139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Administered intravenously
Study NCT05712109 — intervention group
Intervention type: OTHER
Intervention: Follow-up after Anterior cruciate ligament reconstruction
Description: The patients were referred to the sport medicine department for the post ACL-R follow-up including isokinetic knee muscle strength evaluations at 4 months and 8.months after the surgery
Study NCT03463187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: Administered subcutaneously
Study NCT05240092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Haptonomy
Description: Haptonomy, as a field dealing with emotional contact through touch, describe the relationship between parents and the unborn baby.
Study NCT00098891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entinostat
Description: Given orally
Study NCT01790425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: to infuse water into colon to open the lumen for water infusion colonoscopy
Study NCT01790425 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Air colonoscopy
Study NCT02502318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video-thoracoscopy
Study NCT02502318 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracotomy
Study NCT03463187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered subcutaneously
Study NCT03352947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabrafenib
Description: 150mg Dabrafenib twice daily day 1-21 of 28 day cycle in intermittent arm Day 1-28 of 28 day cycle in continuous arm
Study NCT03352947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: 150mg Dabrafenib twice daily day 1-21 of 28 day cycle in intermittent arm Day 1-28 of 28 day cycle in continuous arm
Study NCT00098891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotretinoin
Description: Given orally
Study NCT02866591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mammography according to an auto-compression procedure
Study NCT04326829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1604
Description: QL1604, IV infusion
Study NCT02866591 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mammography according to a standard procedure
Study NCT02866591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionary
Study NCT00697411 — intervention group
Intervention type: OTHER
Intervention: Syndrome cause identification
Study NCT02866591 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionary
Study NCT02822196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Local Anesthesia using 1% Lidocaine
Study NCT02822196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Local Anesthesia using 0.25% Bupivacaine
Study NCT02822196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Local Anesthesia using 0.25% Bupivacaine
Study NCT00996424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Description: Inhalation with N-Acetylcysteine
Study NCT00996424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Inhalation with normal saline solution
Study NCT03468712 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic D2 distal gastrectomy
Description: Laparoscopic D2 distal gastrectomy after 3-Cycle XELOX neo-adjuvant chemotherapy
Study NCT00578968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Participants received once daily Spiriva capsules for oral inhalation: 18 mcg tiotropium powder, for use with HandiHaler device.
Study NCT00578968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to this arm received a once daily oral inhalation of placebo powder to match the standard active comparator dose, using the HandiHaler device.
Study NCT03624855 — intervention group
Intervention type: OTHER
Intervention: Bone or joint infection due to Pseudomonas aeruginosa
Description: Description of bone or joint infection on implant due to Pseudomonas aeruginosa
Study NCT03352947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trametinib
Description: Trametinib 2mg once daily Day 1-14 of a 28 day cycle in intermittent arm Day 1-28 of a 28 day cycle in the continuous arm
Study NCT03352947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib 2mg once daily Day 1-14 of a 28 day cycle in intermittent arm Day 1-28 of a 28 day cycle in the continuous arm
Study NCT02329522 — intervention group
Intervention type: DEVICE
Intervention: Spirometry
Description: Spirometry assesses lung function through measuring the amount (volume) and/or speed (flow) of air that can be inhaled and exhaled. Patients are regarded as COPD if their Forced expiratory volume in 1 second (FEV1) to Forced vital capacity (FVC) ratio are smaller than 70%. Patients were required to perform three blowing manoeuvres, and post-bronchodilator test results were obtained within 20 minutes to 4 hours after inhaling 400 mg of salbultamol.
Study NCT02451306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: See information in arm description.
Study NCT02451306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See information in arm description.
Study NCT01873339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darapladib
Description: The subjects will receive darapladib 160 mg once daily on Days 3-14. It is provided as Enteric coated, free base (micronized) 160 mg tablet.
Study NCT03635567 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT01873339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: The subjects will receive a single oral dose of midazolam 5 mg on Day 1, 3 and14. It is provided as syrup. Each mL of syrup contains midazolam hydrochloride equivalent to 2 mg midazolam
Study NCT02226991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir
Study NCT02226991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study NCT02226991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Study NCT03458143 — intervention group
Intervention type: DRUG
Intervention: Ketamine 150 ng/ml
Description: conscious sedation in TCI-mode
Study NCT03635567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion
Study NCT03635567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion
Study NCT03635567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion
Study NCT03635567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: IV infusion
Study NCT03635567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion
Study NCT03635567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: IV infusion
Study NCT03167060 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active RhinoChill
Description: Participants will be provided with a RhinoChill® device (Active) and an Intranasal Migraine catheter. Once they have the RhinoChill® device, they are asked to treat the next two of your migraines with the device. This requires a maximum of 10 minute intra-nasal treatment as soon as possible after the start of your migraine.~The participation in the trial will last until 3 migraine headaches have been treated with the RhinoChill® device.
Study NCT03635567 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV infusion
Study NCT03635567 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: IV infusion